# AstraZeneca PLC (AZN) stock analysis and sentiment

Canonical page: https://synoptiv.com/stock/AZN
Methodology: https://synoptiv.com/methodology
Author: Synoptiv Research Engine

Last analyzed: Aug 24, 2026

AstraZeneca PLC (AZN) last closed at $165.98, in the lower half of its 52-week range of $145.80–$212.71. Composite market sentiment across 1 analysis is positive (+22 on a −100 to +100 scale), as of Aug 24, 2026.

## What the data says

AstraZeneca closes at $165.98, sitting in the lower half of a 52-week band that runs from $145.80 to $212.71. That places the stock roughly 22% below its 12-month high and about 14% above its low, a range of some 46% between the two extremes — a wide enough spread that the past year has held meaningfully different pricing regimes for the same business.

At a $257 billion market capitalization, the shares trade at about 24.9 times trailing earnings and 5.1 times book value, while the forward multiple of 14.6 implies the market expects earnings to grow well beyond the current base. Underneath those multiples, the company converts roughly 17% of revenue into profit, with revenue growing about 6.4% and a dividend yielding 1.93%. A beta of 0.21 stands out: the stock has historically moved with only a fraction of the broader market's swings, behavior more typical of large-cap pharmaceutical names whose revenue is tied to prescription demand rather than the economic cycle.

Recent news flow is mostly sector-level rather than company-specific. Most headlines concern the wider biopharma landscape — PD-1 and PD-L1 oncology pipeline analyses, autoimmune and oral obesity therapeutics market forecasts, biopharma partnering and licensing deal benchmarks, and a trial failure at an unrelated company. Only one item names AstraZeneca directly: a July 14, 2026 announcement that Pomerantz Law Firm is investigating claims on behalf of investors. Readers weighing the news should note that a single company-specific item sits within a stream otherwise dominated by industry-wide coverage.

## About AstraZeneca PLC

AstraZeneca PLC is a biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. Its portfolio centers on oncology, cardiovascular, renal and metabolic disease, respiratory and immunology, vaccines and immune therapies, and rare diseases. Well-known products include the cancer treatments Tagrisso, Imfinzi, Lynparza, Calquence, and Enhertu; Farxiga/Forxiga and Brilinta/Brilique in cardiovascular and metabolic care; Symbicort, Fasenra, and Tezspire in respiratory and immunology; and Ultomiris and Soliris in rare disease, following the company's acquisition of Alexion.

The company sells to primary and specialty care physicians through distributors and local offices across the United Kingdom, the Americas, the rest of Europe, Asia, Africa, and Australasia. It also pursues research partnerships, including collaborations applying artificial intelligence to oncology drug discovery and treatment response prediction. AstraZeneca was formed through the 1999 merger of Sweden's Astra AB and the UK's Zeneca Group PLC, and is headquartered in Cambridge, United Kingdom.

## Company profile

- Symbol: AZN
- Exchange: NYSE
- Security type: Stock
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Composite sentiment: positive (22 on a -100 to +100 scale)

## Key statistics

| Metric | Value |
| --- | ---: |
| Market capitalization | $257.42B |
| Enterprise value | $284.89B |
| Trailing P/E | 24.88 |
| Forward P/E | 14.61 |
| Price to book | 5.12 |
| Price to sales | 4.19 |
| Dividend yield | 1.93% |
| Beta | 0.21 |
| Net margin | 17.02% |
| Revenue growth | 6.40% |
| Earnings growth | 2.50% |
| 52-week high | $212.71 |
| 52-week low | $145.80 |
| Average volume | 3.01M |

## Related stocks

- AZN.L
- GSK.L
- HLN.L
- HIK.L
- AGY.L
- EAH.L
- POLB.L
- DPH.L

## Recent news

- [Big Pharma is Making Chinese Biotechs Prosper](https://finance.yahoo.com/m/367b6bf3-d1ff-397c-9d7c-80459893a481/big-pharma-is-making-chinese.html) — Aug 20, 2026
- [Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance](https://seekingalpha.com/article/4938625-tempus-ai-just-had-their-entire-strategy-validated-by-moderna-s-vaccine-advance) — Aug 20, 2026
- [Silence Therapeutics: Making Some Recent Noise](https://seekingalpha.com/article/4938417-silence-therapeutics-making-some-recent-noise) — Aug 19, 2026
- [AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?](https://seekingalpha.com/article/4938247-astrazeneca-vs-bristol-myers-squibb-whos-the-better-bargain-for-investors) — Aug 19, 2026
- [HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation](https://finance.yahoo.com/healthcare/articles/healwell-ais-darwen-tm-ai-103000479.html) — Aug 19, 2026
- [The Key to Pharma M&A: Never Shopping Hungry](https://www.wsj.com/health/pharma/the-key-to-pharma-m-a-never-shopping-hungry-34f55ff3?mod=wsj_FV) — Aug 19, 2026
- [BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment](https://www.benzinga.com/m-a/26/08/61282798/biomarin-seeks-to-strengthen-market-position-in-rare-bone-disease-treatment) — Aug 18, 2026
- [Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'](https://seekingalpha.com/article/4937793-monopar-licensing-agreement-and-rolling-nda-submission-serve-as-catalysts-for-strong-buy) — Aug 18, 2026
- [AstraZeneca maintains Citi 'buy' rating despite mixed pipeline updates](https://finance.yahoo.com/m/006948d5-dff3-394e-8500-20aa8e4ab3a0/astrazeneca-maintains-citi.html) — Aug 18, 2026
- [AstraZeneca scores in lung cancer; Sandoz inks a China deal](https://finance.yahoo.com/m/d861779f-2e08-357a-93fe-74de61d2b7b8/astrazeneca-scores-in-lung.html) — Aug 18, 2026

## Frequently asked questions

### What is the current market sentiment for AZN?

As of Aug 24, 2026, AstraZeneca PLC (AZN) carries positive (+22 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report.

### How has AZN stock been performing?

AstraZeneca PLC last closed at $165.98, in the lower half of its 52-week range of $145.80–$212.71.

### What is AZN's market cap and valuation?

AstraZeneca PLC has a market capitalization of about $257.42B, a trailing P/E of 24.9, a dividend yield of 1.93%.

### What sector is AZN in, and who are its competitors?

AstraZeneca PLC operates in the Healthcare sector, specifically Drug Manufacturers - General. Comparable companies include AZN.L, GSK.L, HLN.L, HIK.L, AGY.L.

### Where can I find a full analysis of AZN?

The full AZN report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account.

## Important information

This page is generated from public market and company information. Data can be delayed, incomplete, or wrong. It is research and analysis, not financial advice.

- [Methodology](https://synoptiv.com/methodology)
- [Disclosures](https://synoptiv.com/disclosures)
- [Full report](https://synoptiv.com/stock/AZN/v/1) (account and access required)